(1) Immunopulse and NeoPulse are the exact same device. Only the treatment or drug used is different. Neopulse completed Phase 3 and the result was not very much better than Current Standard of Treatment(Surgery, radiation, chemotherapy). The Neopulse was only cheaper than the CST and ONCS has been trying for many months to get a partner for Neopulse and has not been able to do so
(2) There are many competitors(big companies) in the treatment of melanoma.
Cash as of 10/31/2013 is 15.2M. I had previously estimated 13.5M. According to 10Q, cash need for 1 year period of 07/31/2013 to 07/31/2014 is 10.2 M. This 10.2M includes the 2.2M already spent for the qtr ending 10/31/2013 and also includes the 1M due Inovio on 12/31/2013.
In essence, they have 15.2M in cash and expect to spend 8M from 11/01/2013 to 07/31/2014 which leaves 7.2M remaining on 07/31/2014.
Sounds good to me. No secondary offerings are needed until the 3rd or 4th Qtr in 2014 and maybe into 2015.